TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01963338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal injection in the forearm (0,1cc NaCl 0,9%)
Description: This injection is conducted by the newly developed device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal injection in the forearm (0,1cc NaCl 0,9%)
Description: This injection is conducted by the newly developed device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal injection in the upper arm (0,1cc NaCl 0,9%)
Description: This injection is conducted by the newly developed device in the upper arm (deltoid region).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)
Description: This injection is conducted by needle and syringe in the upper arm (deltoid region).
Study: NCT04272619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIVE-R Life Education
Description: A health educator will present participants with a 30-minute PowerPoint presentation containing educational information about liver cancer risk, screening, prevention, symptoms, and treatments, as well as introduce the concept of neighborhood health (e.g., rates of liver cancer and related risk factors in a census tract and how that might influence individual cancer risk).
Study: NCT04538417

Intervention type: DEVICE
Group type: OTHER
Intervention: Cooled Radiofrequency Ablation
Description: RFA procedures will be performed with modification accounting for appropriate C-RFA technique. Participant will be positioned prone and skin prepped with chloroprep. Ultrasound probe will be placed on residual limb at a transverse angle in order to view the nerve and associated neuroma in long-axis. The probe will be advanced to the site of the stump neuroma. C-RFA electrode will be placed adjacent to neuroma. Needle will be connected via wire to a cooled radiofrequency generator. Motor and sensory testing will be performed to reproduce or exacerbate the RLP and / or PLP. At the site of the neuroma, 2 mL of local anesthetic will be injected through the needle. C-RFA lesions will be created by using the typical C-RFA protocol. Upon completion needle will be removed. Following ablation, 0.5 mL of 0.5% bupivacaine will be injected at the site of the ablated neuroma to provide post procedure analgesia.
Study: NCT03967769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow nasal Cannula
Description: Apnoeic Oxygenation by High Flow Nasal Cannulae

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow nasal Cannula
Description: Apnoeic Oxygenation by High Flow Nasal Cannulae
Study: NCT04748081

Intervention type: PROCEDURE
Intervention: hepatectomy
Description: hepatectomy (ICD-9-CM procedure code: 50.2, 50.22, 50.3 and 50.4)
Study: NCT02022579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE-MRI and DWI
Description: DCE-MRI defined lesion(s) compared with biopsy results or 1-year follow up
Study: NCT05865054

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Combined orbital and cranial vessel wall MRI
Study: NCT03902184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH4102
Description: Patients will receive a flat dose of 750mg
Study: NCT05865054

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Combined orbital and cranial vessel wall MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Combined orbital and cranial vessel wall MRI
Study: NCT00536926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home spirometry with data transfer via cell phone
Description: home spirometry recording
Study: NCT02320422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Telehealth
Description: The telemetric intervention (administered via telephone, or interactive video chat applications such as FaceTime ® or Skype ®) will enable the intervention team (IT) to address non-adherence from a remote location, using a structured, tailored approach
Study: NCT03848702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distal radius fracture brace
Description: The distal radius fracture brace is constructed from biocompatible materials (like polylactic acid; PLA) and the skin is protected by commercially available and approved waterproof padding (like Aquacast®). The major brace components are connected and reinforced with carbon rods and plastic bolt-nut connections. PLA is extensively used, for example in surgical implants, but also as biological alternative for plastics. Aquacast® is approved and used as waterproof padding in swim plaster. The biomechanical function of the distal radius brace has been tested successfully in an ex vivo setting (results to be published). The DRFB includes the distal forearm, wrist an base of the hand. The thumb and fingers are free and the DRFB provides more movement than classical casting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distal radius fracture brace
Description: The distal radius fracture brace is constructed from biocompatible materials (like polylactic acid; PLA) and the skin is protected by commercially available and approved waterproof padding (like Aquacast®). The major brace components are connected and reinforced with carbon rods and plastic bolt-nut connections. PLA is extensively used, for example in surgical implants, but also as biological alternative for plastics. Aquacast® is approved and used as waterproof padding in swim plaster. The biomechanical function of the distal radius brace has been tested successfully in an ex vivo setting (results to be published). The DRFB includes the distal forearm, wrist an base of the hand. The thumb and fingers are free and the DRFB provides more movement than classical casting.
Study: NCT03090867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relatives or surrogates are encouraged to perform care
Description: The relative or surrogate will perform at least two cares a week among feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~The relative or surrogate will give his opinion by completing the study questionnaires.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ,care
Description: The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
Study: NCT03036384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB Prilocaine 2% (varying dose)
Description: Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB Prilocaine 2% (varying dose)
Description: Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB Prilocaine 2% (varying dose)
Description: Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB Prilocaine 2% (varying dose)
Description: Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB Prilocaine 2% (varying dose)
Description: Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
Study: NCT02295046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/Atorvastatin calcium
Description: Amlodipine besylate/Atorvastatin calcium 10/80 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate/Atorvastatin calcium
Description: Amlodipine besylate/Atorvastatin calcium 10/80 mg
Study: NCT03573557

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pink Pad
Description: Pink Pad made by Xodus Medical Inc. used for patients in steep Trendelenburg position during surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bean Bag
Description: Vac-Pac Bean Bag made by Olympic used for patients in steep Trendelenburg position during surgery.
Study: NCT03036384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB Prilocaine 2% (varying dose)
Description: Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB Prilocaine 2% (varying dose)
Description: Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB Prilocaine 2% (varying dose)
Description: Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
Study: NCT00536926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home spirometer with BT-cellphone
Description: Data transfer of home spirometry recordings via bluetooth to clinical database.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home spirometer w/o BT
Description: Standard home spirometry
Study: NCT03573557

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gel Pad
Description: Gel Pad used for patients in steep Trendelenburg position during surgery.
Study: NCT03036384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB Prilocaine 2% (varying dose)
Description: Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
Study: NCT00815490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desaturation
Description: Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
Study: NCT02189083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSD
Description: TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.~High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TSD
Description: TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.~High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks.
Study: NCT02506166

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure Therapy
Description: Positive Airway Pressure Therapy will be used in Group 3 for treatment of predominant obstructive sleep apnea
Study: NCT03323554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ustrap®
Description: Patients will receive Ustrap® under general or loco-regional anaesthesia, by perineal approach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMS 800®
Description: Patients will receive AMS 800® under general or loco-regional anaesthesia. Small openings are made near the scrotum and below the abdomen to insert an inflatable cuff, a pump and a small balloon (pressure regulating balloon).
Study: NCT04366609

Intervention type: DRUG
Intervention: Methylphenidate
Description: Treatment with methylphenidate through dose escalation
Study: NCT04164953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Surgical treatment of Dupuytren's disease. Average from 2 to 4 joints per hand operated on simultaneously
Study: NCT02277769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
Study: NCT02697526

Intervention type: OTHER
Group type: OTHER
Intervention: Terumo

Intervention type: OTHER
Group type: OTHER
Intervention: Tensoplast
Study: NCT03424772

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole genome sequencing
Description: WGS will be performed for the trio
Study: NCT03036384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB Prilocaine 2%
Description: The dose of 45mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 2.5µg sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 2.5µg sufentanyl
Study: NCT02277769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Dupilumab)
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Dupilumab)
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
Study: NCT03069274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: General nutritional recommendations, change drinking habits

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: General nutritional recommendations
Description: Only general nutritional recommendations were given
Study: NCT03120156

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sensomotoric insoles
Description: sensomotoric insoles were published by Jahrling (2007) and have a certain shape that could improve balance abilities. The toes 2-4 are higher that toe 1, so that the tendons of the toe-flectors are pre-stressed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: normal standard insoles
Description: Normal standard insole like you will get them by receipe from an orthotic shop
Study: NCT03652571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Description: Nortriptyline escalating dose regimen:~Week 1-2: 10mg Week 3-4: 25mg Week 5-12: 50mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04255680

Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal Swabs and Blood Draws
Description: Buccal Swabs - Frataxin \& specific RNA markers Blood Draws - Lipid panel, Uric Acid, Protein Marker Analysis and PAX Gene RNA Analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal Swabs and Blood Draws
Description: Buccal Swabs - Frataxin \& specific RNA markers Blood Draws - Lipid panel, Uric Acid, Protein Marker Analysis and PAX Gene RNA Analysis
Study: NCT01333904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR118
Description: inhaled
Study: NCT02355938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin 200 mg
Description: Fidaxomicin 200 mg every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose of placebo every 6 hours x 2 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 125 mg every 6 hours
Study: NCT02180139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: tDCS using a constant current of 2 mA via two 35 cm2 saline soaked sponge electrodes. Treatment is 1x/day for 4 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: tDCS using a constant current of 2 mA via two 35 cm2 saline soaked sponge electrodes. Treatment is 1x/day for 4 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: tDCS using a constant current of 2 mA via two 35 cm2 saline soaked sponge electrodes. Treatment is 1x/day for 4 days.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS using a constant current of 2 mA via two 35 cm2 saline soaked sponge electrodes. Treatment is 1x/day for 4 days.
Study: NCT02246543

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Water, Toast \& Egg (Yolk only) + 0.1g 13C Octanoic Acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HPL
Description: High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LPL
Description: Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HPS
Description: High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LPS
Description: Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
Study: NCT00949403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate
Description: injection of C-11 Palmitate and C-11 Acetate during PET/CT to determine Liver metabolism
Study: NCT03036384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 2.5µg sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 2.5µg sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 2.5µg sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 2.5µg sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 2.5µg sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 2.5µg sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 2.5µg sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 2.5µg sufentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100 µg Morphine
Study: NCT02807298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4%articaine
Description: intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine
Study: NCT03036384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100 µg Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100 µg Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100 µg Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100 µg Morphine
Study: NCT02807298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lignocaine
Description: Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
Study: NCT04126902

Intervention type: OTHER
Intervention: interleukin-6, presepsin and pentraxin-3
Description: measurements and compare

Intervention type: OTHER
Intervention: interleukin-6, presepsin and pentraxin-3
Description: measurements and compare
Study: NCT01612689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer Device
Description: A sensor platform that enables physiological monitoring in routine, home or office environments.
Study: NCT03036384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100 µg Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100 µg Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100 µg Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100 µg Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 100 µg Morphine
Study: NCT02834702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinew acupuncture
Description: The subject is asked to be on sitting posture. The skin around the needling points is disinfected with a 75% alcohol swap. A tube-guided, sterilized, disposal needle is then inserted (at a small angle to the skin) into the acupoint at 0.5-1 cun (depending on point location and body size of the subject). No needle sensation (deqi sensation) is required. A piece of surgical adhesive tape will be applied to the needle immediately after insertion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: The procedure in the sham acupuncture group will be as similar to that of the acupuncture group as possible. In the sham acupuncture group, however, a mock plastic needle guiding tube is tapped on the surface of each acupoint (Ashi point and traditional acupoints) to produce some discernible sensation. A piece of adhesive tape is immediately applied to fix the needle on the dermal surface tapped, without needle insertion. In addition, a plastic tube-guided needle is superficially inserted at the sham point at less than 5mm in depth.
Study: NCT03291743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Description: PillCam(TM) CROHN'S CAPSULE
Study: NCT02809547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dried Blood Spot device